Multi-component HIV Intervention Packages for Chinese Men Who Have Sex With Men —Test, Link and Care (TLC) (MP3)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01904877 |
Recruitment Status
:
Completed
First Posted
: July 22, 2013
Last Update Posted
: April 5, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
- The number of MSM who are tested for HIV in the 4 study clinics over 12 months will increase compared with historical data from the same 4 clinics over the past 12 months prior to the intervention.
- Persons diagnosed with HIV over the duration of 12 months will have higher CD4 counts at diagnosis than persons diagnosed with HIV over the past 12 months prior to the intervention
Condition or disease | Intervention/treatment |
---|---|
HIV/AIDS | Behavioral: Enhancing HIV testing |
Study Type : | Observational [Patient Registry] |
Actual Enrollment : | 3760 participants |
Observational Model: | Ecologic or Community |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 1 Year |
Official Title: | Multi-component HIV Intervention Packages for Chinese Men Who Have Sex With Men —Test, Link and Care (TLC) Version 1.0 Dated 10/15/12 |
Actual Study Start Date : | March 2013 |
Actual Primary Completion Date : | May 2015 |
Actual Study Completion Date : | June 2016 |

Group/Cohort | Intervention/treatment |
---|---|
HIV testing
Enhancing HIV testing: By partnering with the local CDC and the gay community, we will use SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing.
|
Behavioral: Enhancing HIV testing
SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing
Other Name: Phase I
|
Phase II: 367 HIV positive MSM
|
- (Primary) phase I: The number of MSM who are tested for HIV in 4 study clinics over 12 months will increase significantly compared with historical data from the same 4 clinics over the past 12 months prior to the intervention [ Time Frame: 12 months ]The effect of intervention on the monthly number of MSM who receive HIV testing prior to and after intervention at 4 clinics will be evaluated using a generalized estimating equation (GEE) model with robust variance estimates to account for correlation in outcomes within a clinic
- Phase II: A higher proportion of participants in the intervention arm will obtain their CD4 results and ART eligibility assessment in a CDC clinic within 1 month of being diagnosed with HIV than in the comparison arm experienced a local standard of care. [ Time Frame: 1 month ]The proportion of participants randomized to the intervention arm who obtain their CD4 count results within 1 month of randomization will be compared to the same proportion in the comparison arm using logistic regression. The primary analysis will adjust for the following baseline covariates: clinic, CD4 count, ART eligibility, self-reported drug abuse, self-reported alcohol abuse, and age.
- Phase I: Persons diagnosed with HIV over the duration of 12 months will have higher CD4 counts at diagnosis than persons diagnosed with HIV over the past 12 months prior to the intervention. [ Time Frame: 12 month ]We will compare the distribution of CD4 counts immediately after HIV diagnosis for all MSM diagnosed with HIV at one of the 4 clinics for the 12 months during the intervention period versus the 12 months prior to the intervention using a Wilcoxon rank sum test
- Phase II:A higher proportion of ART eligible participants in the intervention arm will receive their first HIV medical care within 3 months of diagnosis than in the comparison arm. [ Time Frame: 12 months ]A logistic regression analysis will be performed to assess the association between intervention and timely receipt of first HIV medical care among those who are ART eligible (CD4<350). The analysis will adjust for the following baseline covariates: clinic, CD4 count, self-reported drug abuse, self-reported alcohol abuse, and age.
- Phase II: A higher proportion of participants in the intervention arm will obtain their CD4 results and ART eligibility assessment in a CDC clinic within 1 month of being diagnosed with HIV than in the comparison arm experienced a local standard of care. [ Time Frame: 36 months ]To evaluate the efficacy of interactive SMS-II with peer education/counseling intervention for reducing risky sexual behaviors among HIV-infected Chinese MSM over the first year of HIV-care
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Inclusion Criteria:• Men who had sex with another man in the last 12 months based on self-reporting (sex can be defined as oral, anal, or mutual masturbation)(including transgendered women)(including transgendered women);
- Aged 18 years or older;
- Living and/or working in the defined districts of municipal Beijing;
- Able and willing to adequately grant informed consent. For the purposes of this activity participants must consent to questionnaire surveys, receipt of phone messages, and serological testing;
- Having not previously participated in HIV testing in this study.
Besides these criteria, additional criteria for the HIV Linkage and Care pilot Research Clinical Trial are:
- Men who are being identified as HIV positive during the testing campaign in Phase I of the study;
- No plan to leave Beijing in the next 12 months.
- Willing to comply with study procedures.
- Having a cell phone and willing to receive study related SMS texts
Exclusion Criteria:
Having previously been found to be HIV positive based on self-reporting during eligibility screening;
- Serious psychological disturbance or cognitive impairment interfering with the participant's ability to comply with the study visit schedule and procedures, as judged by the local study clinician;
- Any other medical or psychiatric condition that, in the opinion of the investigator, would make participation in the study unsafe, or otherwise interfere substantially with the study objectives or interpretation.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01904877
Study Chair: | Sten H Vermund, MD,PhD | Vanderbilt Institue for Global Health | |
Study Director: | Han-Zhu Qian, MD,PhD | Vanderbilt Institue for Global Health | |
Study Director: | Yiming Shao, MD,PhD | Division of Immunology and Microbiology NCAIDS, China CDC |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Vanderbilt University Medical Center |
ClinicalTrials.gov Identifier: | NCT01904877 History of Changes |
Other Study ID Numbers: |
11914 |
First Posted: | July 22, 2013 Key Record Dates |
Last Update Posted: | April 5, 2017 |
Last Verified: | April 2017 |
Keywords provided by Vanderbilt University Medical Center:
HIV testing linkage care |